Download dysuria,frequency - DavisPlus

Name /bks_53161_deglins_md_disk/dimenhydrinate
02/25/2014 09:34AM
Plate # 0-Composite
pg 1 # 1
1
diarrhea, dry mouth. GU: dysuria, frequency. Derm: photosensitivity. Local: pain
at IM site.
dimenhyDRINATE (dye-men-hye-dri-nate)
Interactions
Drug-Drug:qCNS depression with other antihistamines, alcohol, opioid an-
Anti-Nauseant, Calm X, Dimetabs, Dinate, Dramamine, Dramanate,
Gravol, Hydrate, Nauseatol, Traveltabs, Triptone Caplets
Classification
Therapeutic: antiemetics, antihistamines
Pregnancy Category B
Route/Dosage
Indications
Nausea, vomiting, dizziness, and vertigo accompanying motion sickness.
Action
Inhibits vestibular stimulation. Has significant CNS depressant, anticholinergic, antihistaminic, and antiemetic properties. Therapeutic Effects: Decreased vestibular
stimulation, which may prevent motion sickness.
Pharmacokinetics
Absorption: Well absorbed after oral or IM administration.
Distribution: Probably crosses the placenta and enters breast milk.
Metabolism and Excretion: Metabolized by the liver.
Half-life: Unknown.
ONSET
15–60 min
30–45 min
20–30 min
rapid
PEAK
1–2 hr
unknown
1–2 hr
unknown
● Assess nausea, vomiting, bowel sounds, and abdominal pain before and after ad-
DURATION
3–6 hr
6–12 hr
3–6 hr
3–6 hr
Contraindications/Precautions
Contraindicated in: Hypersensitivity; Some products contain alcohol or tartrazine; in patients with known intolerance.
Use Cautiously in: Angle-closure glaucoma; Seizure disorders; Prostatic hyperplasia.
Adverse Reactions/Side Effects
CNS: drowsiness, dizziness, headache, paradoxical excitation (children). EENT:
blurred vision, tinnitus. CV: hypotension, palpitations. GI: anorexia, constipation,
⫽ Canadian drug name.
⫽ Genetic Implication.
PO (Adults): 50– 100 mg q 4 hr (not to exceed 400 mg/day).
PO (Children 6– 12 yr): 25– 50 mg q 6– 8 hr (not to exceed 300 mg/day).
Rect (Adults): 50– 100 mg q 6– 8 hr.
Rect (Children 8– 12 yr): 25– 50 mg q 8– 12 hr.
Rect (Children 6– 8 yr): 12.5– 25 mg q 8– 12 hr.
IM, IV (Adults): 50 mg q 4 hr as needed.
IM, IV (Children): 1.25 mg/kg (37.5 mg/m2) q 6 hr as needed (not to exceed 300
mg/day).
NURSING IMPLICATIONS
Assessment
TIME/ACTION PROFILE (anti– motion sickness, antiemetic activity)
ROUTE
PO
Rect
IM
IV
algesics, and sedative/hypnotics. May mask signs or symptoms of ototoxicity in
patients receiving ototoxic drugs (aminoglycosides, ethacrynic acid).qanticholinergic properties with tricyclic antidepressants, quinidine, or disopyramide. MAO inhibitors intensify and prolong the anticholinergic effects of antihistamines.
ministration of this drug. Dimenhydrinate may mask the signs of an acute abdomen.
● Monitor intake and output, including emesis. Assess for signs of dehydration (excessive thirst, dry skin and mucous membranes, tachycardia, increased urine specific gravity, poor skin turgor).
● Lab Test Considerations: Will cause false-negative allergy skin test results;
discontinue 72 hr before testing.
Potential Nursing Diagnoses
Risk for deficient fluid volume (Indications)
Imbalanced nutrition: less than body requirements (Indications)
Risk for injury (Side Effects)
Implementation
● When used for prophylaxis of motion sickness, administer at least 30 min and
preferably 1– 2 hr before exposure to conditions that may precipitate motion
sickness.
CAPITALS indicate life-threatening, underlines indicate most frequent.
Strikethrough ⫽ Discontinued.
PDF Page #1
Name /bks_53161_deglins_md_disk/dimenhydrinate
02/25/2014 09:34AM
Plate # 0-Composite
pg 2 # 2
2
● PO: Use calibrated measuring device when administering liquid dose.
● IM: Administer into well-developed muscle; massage well.
PDF Page #2
IV Administration
● Direct IV: Diluent: Dilute 50 mg in 0.9% NaCl for injection. Concentration:
5 mg/mL. Rate: Inject over 2 min.
● Y-Site Compatibility: acyclovir, ciprofloxacin, fluconazole, ketamine, metroni-
dazole.
● Solution Compatibility: D5W, 0.45% NaCl, 0.9% NaCl, Ringer’s solution, lac-
tated Ringer’s solution, dextrose/saline combinations, or dextrose/Ringer’s combinations.
Patient/Family Teaching
● Instruct patient to take dimenhydrinate as directed.
● May cause drowsiness. Caution patient to avoid driving or other activities requir-
ing alertness until response to the drug is known.
● Inform patient that this medication may cause dry mouth. Frequent oral rinses,
good oral hygiene, and sugarless gum or candy may minimize this effect.
● Caution patient to avoid alcohol and other CNS depressants concurrently with this
medication.
● Advise patient to use sunscreen and protective clothing to prevent photosensitivity
reactions.
Evaluation/Desired Outcomes
● Prevention or decreased severity of nausea and vomiting, vertigo, or motion sick-
ness.
Why was this drug prescribed for your patient?
䉷 2015 F.A. Davis Company